Insulina Semanal: la nueva promesa

Instagram: ⁠@dr.gilbertogarciabernal⁠Infografías en X: ⁠@DoctorGilbertoGOnce-weekly administration of insulin in the real-world management of type 2 diabetes. A Delphi-like consensus (Acta Diabetol, 2025) Simplifica el tratamiento y mejora la adherencia y calidad de vida.Cost-Effectiveness of Once-Weekly Insulin Icodec versus Daily Basal Insulins in Chinese Adults with T2DM: A Treatment-Background Stratified Analysis (Clinicoecon Outcomes Res, 2025) Alternativa costo-efectiva.Insulin icodec: A novel once‑weekly formulation for the treatment of type 1 and type 2 diabetes mellitus (Rev Endocr Metab Disord, 2025) Potencial para mejorar el cumplimiento terapéutico.Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial (Lancet, 2024) Reducción de HbA1c no inferior, aunque con más hipoglucemia severa. ⁠Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial (Lancet, 2025) ⁠No inferior.⁠Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial (Lancet, 2025) ⁠Alternativa eficaz y bien tolerada.⁠Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. QWINT-2 (N Engl J Med, 2024) ⁠No inferior.⁠Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. QWINT-1 (N Engl J Med, 2025) ⁠Eficacia comparable.⁠Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial (Diabetes Technol Ther, 2025)⁠Factible y eficaz.Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4 (Diabetes Care, 2024) Mantiene métricas de TER e hipoglucemia comparables.The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa (Endocr Rev, 2024) Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial (Lancet, 2023)No inferioridad, pero con más hipoglucemia. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5): A Randomized Trial (Ann Intern Med, 2023) Reducción de HbA1c superior.Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial (Lancet, 2023) Resultó no inferior, permitiendo una reducción en la DTI.⁠Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial (JAMA, 2023) ⁠Reducción de HbA1c superior tras 26 semanas.Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial (Lancet Diabetes Endocrinol, 2023) Fue superior en la reducción de HbA1c.⁠Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. ONWARDS 1 (N Engl J Med, 2023) ⁠Mejor control glucémico.Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment (N Engl J Med, 2020) Eficacia reductora de glucosa y seguridad similar.